Press Releases

  • Mar. 1, 2011 CognitestTM – Diagnostic Blood Test for Alzheimer’s disease – Milestone Attained

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX,V:BTI) is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its CognitestTM blood test for Alzheimer’s disease. Highlights: Simple, easy to use diagnostic blood test for Alzheimer’s ready for clinical testing Human sample testing starting and to run over the… Read more »

  • Feb. 24, 2011 Shareholder Update – 2010 Year in Review

    Vancouver, British Columbia–(Business Wire)– The management of biOasis Technologies Inc. (TSX.V: BTI) is pleased to provide this year in review update to highlight the corporate accomplishments made in 2010. Highlights: Significantly higher concentrations of p97 successfully transported across the Blood-Brain Barrier Commercial development of Cognitest™ (Alzheimer’s disease blood test) underway $1,029,287 private placement completed Dr.… Read more »